ATE534661T1 - Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon - Google Patents
Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davonInfo
- Publication number
- ATE534661T1 ATE534661T1 AT07821082T AT07821082T ATE534661T1 AT E534661 T1 ATE534661 T1 AT E534661T1 AT 07821082 T AT07821082 T AT 07821082T AT 07821082 T AT07821082 T AT 07821082T AT E534661 T1 ATE534661 T1 AT E534661T1
- Authority
- AT
- Austria
- Prior art keywords
- tert
- fusion proteins
- telomerase
- reverse transcriptase
- elicit
- Prior art date
Links
- 108010017842 Telomerase Proteins 0.000 title abstract 13
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102100034343 Integrase Human genes 0.000 title 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title 1
- 239000002773 nucleotide Substances 0.000 title 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 abstract 11
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 201000009030 Carcinoma Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 101710146739 Enterotoxin Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 239000000147 enterotoxin Substances 0.000 abstract 1
- 231100000655 enterotoxin Toxicity 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85118306P | 2006-10-12 | 2006-10-12 | |
| PCT/EP2007/060713 WO2008043760A1 (en) | 2006-10-12 | 2007-10-09 | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534661T1 true ATE534661T1 (de) | 2011-12-15 |
Family
ID=38858912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07821082T ATE534661T1 (de) | 2006-10-12 | 2007-10-09 | Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8017387B2 (de) |
| EP (1) | EP2076531B1 (de) |
| JP (1) | JP2010505433A (de) |
| KR (1) | KR20090079938A (de) |
| CN (1) | CN101522706B (de) |
| AT (1) | ATE534661T1 (de) |
| AU (1) | AU2007306368B2 (de) |
| BR (1) | BRPI0719865A2 (de) |
| CA (1) | CA2664168A1 (de) |
| ES (1) | ES2376010T3 (de) |
| IL (1) | IL198012A0 (de) |
| MX (1) | MX2009003873A (de) |
| NO (1) | NO20091840L (de) |
| NZ (1) | NZ576134A (de) |
| RU (1) | RU2473691C2 (de) |
| WO (1) | WO2008043760A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2049559B1 (de) * | 2006-07-28 | 2012-12-19 | The Trustees of the University of Pennsylvania | Verbesserte hpv-impfstoffe |
| WO2010018136A1 (en) * | 2008-08-12 | 2010-02-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| EP2639299A1 (de) | 2012-03-16 | 2013-09-18 | Invectys | Aus Telomerase abgeleitete, universelle Krebspeptide |
| US20150125438A1 (en) * | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
| CN102942618B (zh) * | 2012-11-14 | 2014-05-21 | 中国人民解放军军事医学科学院生物工程研究所 | 具有肿瘤细胞杀伤活性的端粒蛋白多肽片段及其应用 |
| KR20150130284A (ko) * | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 백신 및 이를 이용한 치료 방법 |
| AU2014242915B2 (en) | 2013-03-28 | 2018-08-09 | Invectys | A cancer vaccine for cats |
| WO2014154905A1 (en) | 2013-03-28 | 2014-10-02 | Invectys | A cancer vaccine for dogs |
| WO2015005723A1 (ko) * | 2013-07-12 | 2015-01-15 | 주식회사 카엘젬백스 | 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트 |
| AU2014343813B2 (en) * | 2013-10-28 | 2020-02-27 | Invectys | A telomerase encoding DNA vaccine |
| EP3063280B1 (de) | 2013-10-28 | 2019-08-14 | Invectys | Gen-elektrotransfer in hautzellen |
| KR102494803B1 (ko) * | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| US10370723B2 (en) | 2014-07-17 | 2019-08-06 | Blueprint Medicines Corporation | TERT fusions |
| WO2017070237A1 (en) * | 2015-10-19 | 2017-04-27 | University Of Maryland, Baltimore | Methods for generating engineered human primary blood dendritic cell lines |
| BR112018013967A2 (pt) * | 2016-01-19 | 2019-02-05 | Pfizer | vacinas contra o câncer |
| KR20180108793A (ko) * | 2016-02-05 | 2018-10-04 | 이노비오 파마수티컬즈, 인크. | 암 백신 및 이를 이용하는 치료 방법 |
| CN110573173A (zh) * | 2016-09-30 | 2019-12-13 | 宾夕法尼亚大学理事会 | Tert免疫原性组合物及使用其的治疗方法 |
| WO2018206512A1 (en) | 2017-05-09 | 2018-11-15 | Invectys | Recombinant measles vaccine expressing htert |
| CA3069363A1 (en) * | 2017-07-11 | 2019-01-17 | Pfizer Inc. | Immunogenic compositions comprising cea muc1 and tert |
| US20220370598A1 (en) * | 2021-05-05 | 2022-11-24 | Inovio Pharmaceuticals, Inc. | Vaccines Against Coronavirus and Methods of Use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340372C (en) | 1984-07-09 | 1999-02-02 | John D. Clements | Production of e. coli lt-b enterotoxin subunit |
| EP0372928A3 (de) | 1988-12-07 | 1990-06-27 | University Of Leicester | Hitze-labile Toxin B-Untereinheit-Fusionsproteine |
| US6413523B1 (en) * | 1989-06-02 | 2002-07-02 | The United States Of America As Represented By The Secretary Of The Navy | Pharmaceutical composition of escherichia coli heat-labile enterotoxin adjuvant and methods of use |
| US5241053A (en) * | 1990-09-05 | 1993-08-31 | Takeda Chemical Industries, Ltd. | Fused proteins comprising glycoprotein gD of HSV-1 and LTB |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
| US7585622B1 (en) * | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| AU734089B2 (en) | 1996-10-01 | 2001-06-07 | Geron Corporation | Human telomerase catalytic subunit |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US7390891B1 (en) * | 1996-11-15 | 2008-06-24 | Amgen Inc. | Polynucleotides encoding a telomerase component TP2 |
| WO1998037181A2 (en) | 1997-02-20 | 1998-08-27 | Whitehead Institute For Biomedical Research | Telomerase catalytic subunit gene and encoded protein |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US7622549B2 (en) * | 1997-04-18 | 2009-11-24 | Geron Corporation | Human telomerase reverse transcriptase polypeptides |
| CA2294646A1 (en) | 1997-06-20 | 1998-12-30 | Bayer Aktiengesellschaft | Human catalytic telomerase sub-unit and its diagnostic and therapeutic use |
| EP0919243A1 (de) * | 1997-11-25 | 1999-06-02 | Duphar International Research B.V | Impfstoff, dessen Adjuvant aus B-Untereinheiten des hitzelabilen Enterotoxins (LTB) von Escherichiacoli besteht |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| AU2002337840B2 (en) | 2001-10-11 | 2007-08-09 | Msd Italia S.R.L. | Hepatitis C virus vaccine |
| AU2003249357A1 (en) * | 2002-06-27 | 2004-01-19 | Geron Corporation | Cancer vaccine containing cross-species epitopes of telomerase reverse transcriptase |
| NZ549048A (en) * | 2004-02-11 | 2009-04-30 | Angeletti P Ist Richerche Bio | Carcinoembryonic antigen fusion proteins and uses thereof |
| DE102004035227A1 (de) * | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| US20090304733A1 (en) | 2004-07-28 | 2009-12-10 | Jacob Pitcovski | Vaccine comprising recombinant ct or lt toxin |
| KR20080018201A (ko) | 2005-05-19 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｅ．ｃｏｌｉ 열 독소의 ｂ서브유닛 및 항원 및애주번트를 포함하는 백신 조성물 |
| CN1757736A (zh) * | 2005-07-26 | 2006-04-12 | 浙江大学 | 一种融合基因载体的构建表达及应用 |
-
2007
- 2007-10-09 WO PCT/EP2007/060713 patent/WO2008043760A1/en active Application Filing
- 2007-10-09 EP EP07821082A patent/EP2076531B1/de active Active
- 2007-10-09 KR KR1020097009725A patent/KR20090079938A/ko not_active Application Discontinuation
- 2007-10-09 AT AT07821082T patent/ATE534661T1/de active
- 2007-10-09 MX MX2009003873A patent/MX2009003873A/es active IP Right Grant
- 2007-10-09 CA CA002664168A patent/CA2664168A1/en not_active Abandoned
- 2007-10-09 NZ NZ576134A patent/NZ576134A/en not_active IP Right Cessation
- 2007-10-09 ES ES07821082T patent/ES2376010T3/es active Active
- 2007-10-09 BR BRPI0719865A patent/BRPI0719865A2/pt not_active IP Right Cessation
- 2007-10-09 RU RU2009117325/10A patent/RU2473691C2/ru not_active IP Right Cessation
- 2007-10-09 CN CN2007800378827A patent/CN101522706B/zh not_active Expired - Fee Related
- 2007-10-09 JP JP2009531827A patent/JP2010505433A/ja active Pending
- 2007-10-09 AU AU2007306368A patent/AU2007306368B2/en not_active Ceased
- 2007-10-11 US US11/974,067 patent/US8017387B2/en not_active Expired - Fee Related
-
2009
- 2009-04-05 IL IL198012A patent/IL198012A0/en unknown
- 2009-05-11 NO NO20091840A patent/NO20091840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2664168A1 (en) | 2008-04-17 |
| NZ576134A (en) | 2011-09-30 |
| CN101522706A (zh) | 2009-09-02 |
| MX2009003873A (es) | 2009-04-22 |
| RU2473691C2 (ru) | 2013-01-27 |
| JP2010505433A (ja) | 2010-02-25 |
| WO2008043760A1 (en) | 2008-04-17 |
| AU2007306368B2 (en) | 2012-05-03 |
| KR20090079938A (ko) | 2009-07-22 |
| BRPI0719865A2 (pt) | 2016-03-15 |
| EP2076531A1 (de) | 2009-07-08 |
| IL198012A0 (en) | 2011-08-01 |
| EP2076531B1 (de) | 2011-11-23 |
| CN101522706B (zh) | 2013-09-04 |
| US8017387B2 (en) | 2011-09-13 |
| NO20091840L (no) | 2009-07-10 |
| US20080090778A1 (en) | 2008-04-17 |
| AU2007306368A1 (en) | 2008-04-17 |
| RU2009117325A (ru) | 2010-11-20 |
| ES2376010T3 (es) | 2012-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE534661T1 (de) | Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon | |
| ATE555127T1 (de) | Fusionsproteine des karzinomembryonalen antigens und deren verwendungen | |
| EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
| BR112019001922A2 (pt) | receptores de célula t e imunoterapia usando os mesmos | |
| Jegerlehner et al. | Bacterially produced recombinant influenza vaccines based on virus-like particles | |
| Fan et al. | Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes | |
| WO2006089230A3 (en) | Human monoclonal antibodies to prostate specific membrane antigen (psma) | |
| WO2002074795A3 (en) | Oligomeric complexes of chimeric proteins with enhanced immunogenic potential | |
| ATE461215T1 (de) | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden | |
| MX2019003156A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| Yong et al. | Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles | |
| ATE470673T1 (de) | Impfstoffe mit lawsoniaintrazellularis- untereinheit | |
| NO20055708L (no) | Syntetisk gen som koder for humant karsinembryonalt antigen og anvendelser derav | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
| MX2020012913A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| DK1536006T3 (da) | Cancerantigener og anvendelse deraf | |
| MX2009003679A (es) | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. | |
| MX2021003281A (es) | Anticuerpos anti-cd45rc humanos y usos de los mismos. | |
| WO2014140894A3 (en) | Self-assembling synthetic proteins | |
| ATE462792T1 (de) | Rekombinanter chemokin-antigenimpfstoff | |
| ATE450545T1 (de) | Impfstoff mit lawsonia intracellularis- untereinheit | |
| ATE525401T1 (de) | Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene | |
| ATE331796T1 (de) | Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon | |
| Rezaee et al. | Cloning, expression and purification of binding domains of lethal factor and protective antigen of Bacillus anthracis in Escherichia coli and evaluation of their related murine antibody |